Pipeline
| Disease Area | Indication | Target factor | Seed | Pre-Clinical | Phase I |
|---|---|---|---|---|---|
| Local tissue regeneration | |||||
| Osteo arthritis | |||||
| mRNA: RUNX1 | |||||
| Partner: Axcelead Inc. | |||||
| Skin | |||||
| mRNA: F | |||||
| Ophthalmic | |||||
| mRNA: C | |||||
| Partner: Not disclosed | |||||
| Vaccine | |||||
| Allergy | |||||
| mRNA: B | |||||
| Partner: Kao Corporate | |||||
| Infection | |||||
| mRNA: A | |||||
| Partner: Crafton Biotechnology / MAB | |||||
| Allergy | |||||
| mRNA: G | |||||
| Partner: Kao Corporate | |||||
| Autoimmune disease | |||||
| mRNA: H | |||||
| Partner: Kao Corporate | |||||
| Oncology | |||||
| GBM | |||||
| ASO: TUG1 | |||||
| Partner: Nagoya University | |||||
| HER2-negative breast cancer |
|||||
| siRNA: PRDM14 | |||||
| Partner: Keio University | |||||